---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-002761"
form_type: "8-K"
ticker: "CPMV"
cik: "0000836564"
company_name: "Mosaic ImmunoEngineering Inc."
filed_at: "2024-04-29T23:59:59+00:00"
generated_at: "2026-06-03T06:02:39.909756+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mosaic to acquire Oncotelic's clinical necroptosis cancer assets for up to $30M in stock

## Summary
- Binding term sheet signed April 26, 2024; acquisition includes VDA necroptosis therapies and AI platform.
- Initial $15M in common or preferred stock; milestone payments up to $15M more in shares.
- Oncotelic to provide operational loan through June 1 and assist in raising $2M initial funding.
- If funding fails, transaction may convert to reverse acquisition/merger; shareholder approval required.
- Mosaic gains regulatory packages and access to Oncotelic's AI for immunotherapy combination discovery.

## SEC filing metadata
- accession: 0001683168-24-002761
- form_type: 8-K
- ticker: CPMV
- cik: 0000836564
- company_name: Mosaic ImmunoEngineering Inc.
- filed_at: 2024-04-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/836564/000168316824002761/0001683168-24-002761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/836564/000168316824002761/mosaic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-002761
- JSON: https://secwatch.observer/filing/0001683168-24-002761.json
- Plain text: https://secwatch.observer/filing/0001683168-24-002761.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.